CN104254544B - Cdim结合蛋白及其用途 - Google Patents

Cdim结合蛋白及其用途 Download PDF

Info

Publication number
CN104254544B
CN104254544B CN201380008515.XA CN201380008515A CN104254544B CN 104254544 B CN104254544 B CN 104254544B CN 201380008515 A CN201380008515 A CN 201380008515A CN 104254544 B CN104254544 B CN 104254544B
Authority
CN
China
Prior art keywords
binding proteins
antigen
cdim
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380008515.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104254544A (zh
Inventor
纳尔逊·N·H·邓
倪丽娜·M·巴特
玛西亚·M·比伯
布鲁斯·A·凯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Moker Bioscience Co ltd
Original Assignee
IGM Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IGM Biosciences Inc filed Critical IGM Biosciences Inc
Publication of CN104254544A publication Critical patent/CN104254544A/zh
Application granted granted Critical
Publication of CN104254544B publication Critical patent/CN104254544B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380008515.XA 2012-02-08 2013-02-08 Cdim结合蛋白及其用途 Active CN104254544B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261633330P 2012-02-08 2012-02-08
US61/633,330 2012-02-08
PCT/US2013/025430 WO2013120012A2 (en) 2012-02-08 2013-02-08 Cdim binding proteins and uses thereof

Publications (2)

Publication Number Publication Date
CN104254544A CN104254544A (zh) 2014-12-31
CN104254544B true CN104254544B (zh) 2017-04-26

Family

ID=48045015

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380008515.XA Active CN104254544B (zh) 2012-02-08 2013-02-08 Cdim结合蛋白及其用途

Country Status (14)

Country Link
US (1) US9409976B2 (enExample)
EP (1) EP2812356B1 (enExample)
JP (1) JP6335796B2 (enExample)
KR (1) KR102102111B1 (enExample)
CN (1) CN104254544B (enExample)
AU (1) AU2013200903B2 (enExample)
BR (1) BR112014019459B1 (enExample)
CA (1) CA2863714C (enExample)
DK (1) DK2812356T3 (enExample)
ES (1) ES2735289T3 (enExample)
IN (1) IN2014MN01781A (enExample)
MX (1) MX363819B (enExample)
TW (1) TWI606064B (enExample)
WO (1) WO2013120012A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2922830A1 (en) 2013-09-05 2015-04-16 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
CN113072644A (zh) 2013-12-17 2021-07-06 埃姆医疗有限公司 抵抗骨髓增生障碍或淋巴组织增生障碍的手段和方法
AU2015213593B2 (en) 2014-02-10 2020-09-03 Igm Biosciences, Inc. IgA multi-specific binding molecules
KR102380402B1 (ko) 2014-04-03 2022-03-31 아이쥐엠 바이오사이언스 인코포레이티드 변형된 j-사슬
EP3750918A1 (en) 2015-01-20 2020-12-16 IGM Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CN115093479A (zh) 2015-03-04 2022-09-23 Igm生物科学股份有限公司 Cd20结合分子及其用途
JP6882184B2 (ja) 2015-03-25 2021-06-02 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ｂ型肝炎ウイルス抗原結合分子およびその使用
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
DK3355913T3 (da) 2015-09-30 2024-12-02 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
PL3455257T3 (pl) 2016-05-09 2022-01-17 Igm Biosciences Inc. Przeciwciała anty-pd-l1
DE202017007542U1 (de) 2016-08-15 2022-07-19 Novartis Ag Behandlungsschemata zur Behandlung von Multipler Sklerose unter Verwendung von Ofatumumab
WO2018148447A1 (en) * 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor
EP4491234A3 (en) 2017-02-08 2025-04-09 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
BR112019017197A2 (pt) 2017-02-20 2020-04-14 Dragonfly Therapeutics, Inc. proteínas que se ligam a her2, nkg2d e cd16
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
AU2019218125B2 (en) 2018-02-08 2025-03-13 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
TW201942134A (zh) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
WO2019169314A1 (en) 2018-03-01 2019-09-06 Igm Biosciences, Inc. IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
KR20250112921A (ko) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
EP4640698A3 (en) * 2018-11-16 2026-02-25 Memorial Sloan Kettering Cancer Center Antibodies to mucin-16 and methods of use thereof
CN114269785A (zh) 2019-08-15 2022-04-01 Igm生物科学股份有限公司 免疫刺激性多聚体结合分子
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
CN114181318B (zh) * 2021-11-08 2023-08-01 四川大学 一种组织特异性表达穿透血脑屏障的idua融合蛋白的重组腺相关病毒及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044998A2 (en) * 2003-11-05 2005-05-19 Palingen, Inc. Enhanced b cell cytotoxicity of cdim binding antibody
WO2007035857A2 (en) * 2005-09-19 2007-03-29 Palingen, Inc. Treatment of b cell diseases using anti-germline antibody binding agents
US20100322849A1 (en) * 2003-11-05 2010-12-23 Bhat Neelima M Enhanced b cell cytotoxicity of cdim binding antibody

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5246692A (en) 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5417972A (en) * 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US6962979B1 (en) 1995-03-14 2005-11-08 Cohesion Technologies, Inc. Crosslinkable biomaterial compositions containing hydrophobic and hydrophilic crosslinking agents
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6680335B2 (en) 1998-09-28 2004-01-20 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
IL148718A0 (en) 1999-09-17 2002-09-12 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
US20030223994A1 (en) * 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
WO2006052641A2 (en) * 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
DE602005027258D1 (de) * 2005-03-14 2011-05-12 Us Gov Health & Human Serv Humane monoklonale antikörper gegen hendra- und nipah-viren
WO2008123999A2 (en) * 2007-04-02 2008-10-16 Amgen Fremont Inc. Anti-ige antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044998A2 (en) * 2003-11-05 2005-05-19 Palingen, Inc. Enhanced b cell cytotoxicity of cdim binding antibody
US20100322849A1 (en) * 2003-11-05 2010-12-23 Bhat Neelima M Enhanced b cell cytotoxicity of cdim binding antibody
WO2007035857A2 (en) * 2005-09-19 2007-03-29 Palingen, Inc. Treatment of b cell diseases using anti-germline antibody binding agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Recognition of Auto- and Exoantigens by V4-34 Gene Encoded Antibodies;N. M. BHAT,et al.;《Scand. J. Immunol.》;20001231;第51卷;第134-140页 *
Susceptibility of B-cell lymphoma to human antibodies encoded by the V4-34 gene;Neelima M. Bhat, et al.;《Critical Reviews in Oncology/Hematology》;20011231;第39卷;第59-68页 *

Also Published As

Publication number Publication date
TWI606064B (zh) 2017-11-21
BR112014019459B1 (pt) 2023-04-18
DK2812356T3 (da) 2019-07-08
MX2014009628A (es) 2015-03-19
EP2812356A2 (en) 2014-12-17
ES2735289T3 (es) 2019-12-17
CA2863714A1 (en) 2013-08-15
US20140044739A1 (en) 2014-02-13
CN104254544A (zh) 2014-12-31
CA2863714C (en) 2022-07-05
WO2013120012A3 (en) 2013-11-07
AU2013200903A1 (en) 2013-08-22
HK1205136A1 (en) 2015-12-11
US9409976B2 (en) 2016-08-09
AU2013200903B2 (en) 2015-05-14
MX363819B (es) 2019-04-03
KR20150001728A (ko) 2015-01-06
WO2013120012A2 (en) 2013-08-15
TW201345921A (zh) 2013-11-16
JP6335796B2 (ja) 2018-06-06
EP2812356B1 (en) 2019-03-27
IN2014MN01781A (enExample) 2015-07-03
BR112014019459A8 (pt) 2023-01-10
JP2015511817A (ja) 2015-04-23
BR112014019459A2 (pt) 2017-06-27
KR102102111B1 (ko) 2020-04-20

Similar Documents

Publication Publication Date Title
CN104254544B (zh) Cdim结合蛋白及其用途
US12428478B2 (en) Anti-Claudin 18.2 antibody and application thereof
US10947299B2 (en) Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus and use for same
JP7352973B2 (ja) 二重特異性抗体及びその使用
CN109069620B (zh) 拮抗剂ccr7受体的人源化抗体
NZ793343A (en) Anti- LAG-3 antibodies and compositions
BR112020015736A2 (pt) Anticorpo anti-b7-h4, fragmento de ligação a antígeno do mesmo e uso farmacêutico do mesmo
JP2016531920A (ja) Ｃｄ７０結合ペプチドおよびそれに関連する方法、プロセスおよび用途
ES2577290T3 (es) Anticuerpo anti-ICAM inductor de apóptosis
EP4450522A2 (en) Antibody against ox40 and medical use thereof
JP6486914B2 (ja) ヒト抗ｉｌ−３２抗体
CN114106165A (zh) 一种靶向甲型流感病毒n1亚型na蛋白的抗体
JP7599186B2 (ja) コロナウイルススパイクタンパク質に特異的な抗体及びその用途
US20240182550A1 (en) Antibodies, fragments or derivatives specifically binding to a protein antigen capable of binding to nucleic acids and uses of same
KR20190063765A (ko) 항-ceacam1 항체 및 이의 용도
EP4613774A1 (en) Single domain antibody targeting human ror1
TW202542202A (zh) 抗體、抗原結合片段及其醫療用途
AU2015210362A1 (en) Cdim binding proteins and uses thereof
HK1205136B (en) Cdim binding proteins and uses thereof
JP2024522180A (ja) Ｎｋ細胞によって媒介される細胞傷害性を刺激する抗体
WO2024150074A2 (en) Coronavirus antibodies and therapeutic uses thereof
HK40041672B (zh) 新型抗cd39抗体
CA3105415A1 (en) Antibodies specific to folate receptor alpha

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20180315

Address after: Danish spirits

Patentee after: IGM Biology Science Co., Ltd.

Address before: American California

Patentee before: IGM BIOSCIENCES INC.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20180928

Address after: American California

Patentee after: IGM BIOSCIENCES INC.

Address before: Danish spirits

Patentee before: IGM Biosciences Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220301

Address after: California, USA

Patentee after: Moker bioscience Co.,Ltd.

Address before: California, USA

Patentee before: IGM BIOSCIENCES, Inc.